Eslicarbazepine

SKU: orb1304345

Description

Eslicarbazepine acetate (Stedesa) is a voltage-gated sodium channel blocker approved as an adjunctive treatment for partial-onset seizures in adults. It is widely used in neuroscience research for in vitro electrophysiology studies and in vivo models of epilepsy to investigate its anticonvulsant mechanisms.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 104746-04-5
• MW: 254.28
• Purity: 99.97%
• Formula: C₁₅H₁₄N₂O₂
• SMILES: NC(=O)N1c2ccccc2C[C@H](O)c2ccccc12
• Target: Sodium Channel,Beta-Secretase
• Solubility: DMSO:12 mg/mL (47.19 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.87 mM)

Bioactivity

• In Vitro:
  Eslicarbazepine is an anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile. Eslicarbazepine acetate is a prodrug for eslicarbazepine (S-licarbazepine), which is a dual Inhibitor of β-Secretase and voltage-gated sodium channel.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Stedesa, SodiumChannel, Sodium Channel, Voltage-gated sodium channel, βSecretase, β-Secretase, inhibit, Pazzul, Inhibitor, Erelib, Eslicarbazepine, EC 810-248-9, BIA 2-194, Beta-secretase, BetaSecretase, bSecretase, b-Secretase

Compound Identifiers

PubChem CID

9881504